Farampator (CX-691)


Methylsulfonamide AMPA potentiator

An Organon/Schering-Plough ampakine (CX-691) that reached Phase 2 in major depressive disorder and Alzheimer disease.

Abstract

Farampator (CX-691, ORG-24448; CAS 211735-76-1; molecular formula C16H22N2O3S; molecular weight 322.42) is a methylsulfonamide-class AMPA receptor positive allosteric modulator developed by Cortex Pharmaceuticals and licensed to Organon (subsequently Schering-Plough, then Merck). The compound advanced through Phase 2 trials in major depressive disorder, Alzheimer disease, and adult ADHD with mixed results; the development program was discontinued after the Schering-Plough acquisition by Merck. Mechanism is AMPA receptor positive allosteric modulation with characteristics intermediate between the early CX-516 class and the later sustained-action ampakines. Pharmacokinetics: plasma half-life approximately 5 to 6 hours; oral bioavailability adequate. The compound is sold as a research chemical with limited availability. The clinical evidence base in depression specifically is interesting: rapid antidepressant-like effects analogous to those seen with ketamine were observed in Phase 2, suggesting the ampakine mechanism may share some clinical pharmacology with NMDA-blocking rapid antidepressants.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph